Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis

• Published in: Frontiers in immunology Vol. 11; p. 18
• Main Authors: Zhang, Wenting, Huang, Qinghua, Xiao, Weiwei, Zhao, Yue, Pi, Jiang, Xu, Huan, Zhao, Hongxia, Xu, Junfa, Evans, Colin E., Jin, Hua
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 28.01.2020
• Subjects: Adaptive Immunity - drug effects; Animals; Antibodies, Monoclonal, Humanized - therapeutic use; Antigens, Differentiation - chemistry; Antigens, Differentiation - metabolism; Antineoplastic Agents, Immunological - therapeutic use; CD47; CD47 Antigen - antagonists & inhibitors; CD47 Antigen - chemistry; CD47 Antigen - immunology; CD47 Antigen - metabolism; CD47/SIRPa axis; Humans; Immunology; immunotherapy; Immunotherapy - methods; Macrophages - immunology; Neoplasms - drug therapy; phagocytosis; Phagocytosis - drug effects; Receptors, Immunologic - chemistry; Receptors, Immunologic - metabolism; Signal Transduction - drug effects; signal-regulatory protein α (SIRPα); Xenograft Model Antitumor Assays; phagocytosis; CD47; CD47/SIRPa axis; immunotherapy; signal-regulatory protein α (SIRPα)

CD47 is an immunoglobulin that is overexpressed on the surface of many types of cancer cells. CD47 forms a signaling complex with signal-regulatory protein α (SIRPα), enabling the escape of these cancer cells from macrophage-mediated phagocytosis. In recent years, CD47 has been shown to be highly ex...